ACTU vs IT · $49.0M cap vs P/E 16, rev $6.27B
Actuate Therapeutics, Inc. Common stock (ACTU) versus Gartner Inc (IT) — a side-by-side from cached financials, not a winner call.
Actuate Therapeutics, Inc. Common stock (ACTU) is a biotechnology company listed on NASDAQ.
Gartner Inc (IT) is a information technology services company listed on US.
ACTU does not have a complete income-statement cache yet.
Latest reported IT revenue for 2024-12-31 was $6.27B. Net income was $1.25B. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. IT currently screens at market cap $11.03B and trailing P/E 16.3.
ACTU currently screens at market cap $49.0M. IT currently screens at market cap $11.03B and trailing P/E 16.3.
Not investment advice. Open the ACTU and IT stock pages for the full models.
Not investment advice.